Nul, a UK-based HealthTech startup building a supported alcohol reduction platform that offers access to clinical care and prescription medication, today announced that it has raised nearly €840k ($1 million) in Seed funding to support UK launch, team expansion, and international growth plans.
The round was led by dmg ventures, the venture arm of Daily Mail and General Trust, and BYVP, along with a group of angel investors with backgrounds in technology, healthcare, and consumer brands.
Matus Maar, founder and CEO of Nul, said, “Alcohol reduction is one of the largest and least modernised areas in healthcare. Telehealth and online pharmacy platforms have transformed categories like weight loss and mental health, yet alcohol has been left behind despite the scale of the problem. Nul is about making evidence-based treatment accessible, discreet and compatible with real life.”
Founded by Maar, co-founder of Talis Capital, Nul is building a telehealth platform that combines clinical care and prescription medication with digital pathways and behavioural support to help people reduce their alcohol consumption.
According to Nul, its core programme is built around naltrexone, an FDA-approved medication to treat opioid use disorder (OUD) as well as alcohol use disorder (AUD). Similar to GLP1, naltrexone plays on reward pathways and is used to reduce alcohol cravings. Nul claims that its programme is delivered through a fully remote, subscription-based service that includes virtual consultation, ongoing clinical support, and structured digital support based on The Sinclair Method, which clinical studies have reported to have a success rate of up to 78% (Sinclair, John – Clinical Studies, 2001). Its partners include Blueco Healthcare and Thriva.
Rachel Muzyczka, Partner at dmg ventures, said, “Nul’s mission to empower individuals to take control of their relationship with alcohol is both timely and transformative. Their approach is not only innovative but deeply aligned with the growing demand for healthier lifestyles. We see tremendous potential in their approach and the market they’re serving.”
With the Seed funding, the company will support a full UK commercial launch, expand its clinical and product teams, acquire customers at scale, and prepare for international expansion, including the US.
In parallel with the Seed round, Nul says it plans to launch a crowdfunding campaign on Republic Europe later this week, enabling retail investors to participate in the round and support the company’s next phase of growth. It plans to raise further capital in 2026 as it scales in the UK and enters new markets
Nul notes that it launched a UK test phase in summer 2025 and has onboarded more than 120 paying customers. It reported reaching an annualised revenue run-rate of nearly €344k (over £300,000) within its first few months, driven largely by organic demand and word of mouth. The startup plans to raise further capital in 2026 as it scales in the UK and enters new markets.
Read the orginal article: https://www.eu-startups.com/2026/02/exclusive-uk-healthtech-startup-nul-raises-e840k-in-seed-funding-to-nullify-alcohol-dependence/
